

Global Sustained Release Ophthalmic Drugs Market Growth 2026-2032

<https://marketpublishers.com/r/G29E525E04BDEN.html>

Date: July 2026

Pages: 123

Price: US\$ 3,660.00 (Single User License)

ID: G29E525E04BDEN

Abstracts

The global Sustained Release Ophthalmic Drugs market size is predicted to grow from US\$ 1467 million in 2025 to US\$ 2530 million in 2032; it is expected to grow at a CAGR of 7.8% from 2026 to 2032.

Sustained Release Ophthalmic Drugs refer to a general category of pharmaceutical products that utilize modern formulation technologies or medical device platforms to continuously release active pharmaceutical ingredients to the eye at a controlled rate, thereby extending the duration of therapeutic action. Unlike conventional eye drops which have short residence time on the ocular surface and low bioavailability, Sustained Release Ophthalmic Drugs form drug depots within the eye by overcoming complex physiological barriers such as the corneal barrier and tear clearance system. This technology platform can extend traditional therapeutic regimens requiring multiple daily administrations to single administrations lasting weeks, months, or even longer periods. From an industrial attribute perspective, Sustained Release Ophthalmic Drugs sit at the intersection of pharmaceuticals, polymer materials science, bioengineering, and clinical ophthalmology, encompassing multiple dosage forms and device formats including implants, punctal plugs, in situ gels, nanosuspensions, and drug eluting contact lenses. Their core value lies in significantly improving patient medication adherence, reducing the risk of side effects from frequent administration, and achieving precise drug delivery to target sites.

Market Development Opportunities and Main Drivers

Global population aging and the increasing prevalence of chronic eye diseases directly drive clinical demand for long acting therapeutic solutions. The accelerated approval pathways of the US Food and Drug Administration and the European Medicines Agency

provide policy support for innovative products. The application of biodegradable polymers, nanotechnology, and smart stimuli responsive materials has significantly improved system controllability and safety. Allergan's Durysta, as the first approved intracameral sustained release implant, received US Food and Drug Administration approval for open angle glaucoma. Alcon, Roche, and Santen have built dense patent portfolios around sustained release devices and biologics.

Market Challenges and Risks

Sustained Release Ophthalmic Drugs face core challenges including long product development cycles and high regulatory barriers. The review pathway for combination products is complex, requiring simultaneous fulfillment of both drug safety and medical device performance requirements. Some non biodegradable implants require surgical removal after drug depletion, increasing patient risk and healthcare burden. The supply of precision manufacturing processes and high purity polymer excipients is relatively concentrated, creating sustained cost control pressure. Marketed products face technology substitution risk, as exemplified by the OTX TP punctal plug, which was discontinued after failing to meet clinical trial endpoints. Furthermore, the non adjustable dosing nature of sustained release systems imposes limitations on personalized treatment, as once implanted it is difficult to adjust or terminate drug delivery.

Downstream Demand Trends

The glaucoma treatment field shows the most urgent need to reduce daily eye drop dependence, with intracameral implants and punctal plugs becoming the primary technology pathways. Patients with age related macular degeneration and diabetic retinopathy show growing demand for intravitreal sustained release implants, as existing anti vascular endothelial growth factor therapies require monthly injections and suffer from poor patient compliance. Anterior segment diseases such as dry eye disease and postoperative inflammation control are driving clinical adoption of conjunctival fornix inserts and drug eluting contact lenses. Notably, gene therapy and cell therapy are converging with sustained release delivery technologies, and encapsulated cell therapy implants have entered clinical use, capable of secreting therapeutic proteins over the long term.

Regional Trends

The North American market, with its mature regulatory approval pathways, comprehensive reimbursement coverage, and concentration of major innovative

companies, leads in the commercialization of Sustained Release Ophthalmic Drugs. The European market, influenced by deepening aging demographics and shifting healthcare spending priorities, shows strong demand for cost effective long acting therapeutic solutions. The Asia Pacific region, benefiting from improved ophthalmic diagnostic and treatment capabilities and enhanced patient purchasing power in countries including China and India, is emerging as a growth region. Santen Pharmaceutical and other companies are accelerating product regional penetration by focusing on the Asian market and conducting local clinical studies.

LP Information, Inc. (LPI) ' newest research report, the "Sustained Release Ophthalmic Drugs Industry Forecast" looks at past sales and reviews total world Sustained Release Ophthalmic Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Sustained Release Ophthalmic Drugs sales for 2026 through 2032. With Sustained Release Ophthalmic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Sustained Release Ophthalmic Drugs industry.

This Insight Report provides a comprehensive analysis of the global Sustained Release Ophthalmic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sustained Release Ophthalmic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Sustained Release Ophthalmic Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sustained Release Ophthalmic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sustained Release Ophthalmic Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Sustained Release Ophthalmic Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Implants

Punctal Plug

Liposome

In Situ Gel

Segmentation by Release Mechanism:

Diffusion Controlled Drug

Degradation Controlled Drug

Swelling Controlled Drug

Stimuli Responsive Drug

Segmentation by Application:

Cataract Therapy

Glaucoma Therapy

Dry Eye Disease Therapy

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

EyePoint

AbbVie

Ocular Therapeutix

Neurotech Pharmaceuticals

Santen Pharmaceutical

Clearside Biomedical

PolyActiva

Kodiak Sciences

Adverum

Bausch + Lomb

Kanghong

Ocumension

Key Questions Addressed in this Report

What is the 10-year outlook for the global Sustained Release Ophthalmic Drugs market?

What factors are driving Sustained Release Ophthalmic Drugs market growth,

globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Sustained Release Ophthalmic Drugs market opportunities vary by end market size?

How does Sustained Release Ophthalmic Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Sustained Release Ophthalmic Drugs Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Sustained Release Ophthalmic Drugs by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Sustained Release Ophthalmic Drugs by Country/Region, 2021, 2025 & 2032

2.2 Sustained Release Ophthalmic Drugs Segment by Type

- 2.2.1 Implants
 - 2.2.2 Punctal Plug
 - 2.2.3 Liposome
 - 2.2.4 In Situ Gel
 - 2.2.5 Sustained Release Ophthalmic Drugs Sales by Type
 - 2.2.5.1 Global Sustained Release Ophthalmic Drugs Sales Market Share by Type (2021-2026)
 - 2.2.5.2 Global Sustained Release Ophthalmic Drugs Revenue and Market Share by Type (2021-2026)
 - 2.2.5.3 Global Sustained Release Ophthalmic Drugs Sale Price by Type (2021-2026)
- #### 2.3 Sustained Release Ophthalmic Drugs Segment by Release Mechanism
- 2.3.1 Diffusion Controlled Drug
 - 2.3.2 Degradation Controlled Drug
 - 2.3.3 Swelling Controlled Drug
 - 2.3.4 Stimuli Responsive Drug
 - 2.3.5 Sustained Release Ophthalmic Drugs Sales by Release Mechanism
 - 2.3.5.1 Global Sustained Release Ophthalmic Drugs Sales Market Share by Release

Mechanism (2021-2026)

2.3.5.2 Global Sustained Release Ophthalmic Drugs Revenue and Market Share by Release Mechanism (2021-2026)

2.3.5.3 Global Sustained Release Ophthalmic Drugs Sale Price by Release Mechanism (2021-2026)

2.4 Sustained Release Ophthalmic Drugs Segment by Application

2.4.1 Cataract Therapy

2.4.2 Glaucoma Therapy

2.4.3 Dry Eye Disease Therapy

2.4.4 Others

2.4.5 Sustained Release Ophthalmic Drugs Sales by Application

2.4.5.1 Global Sustained Release Ophthalmic Drugs Sale Market Share by Application (2021-2026)

2.4.5.2 Global Sustained Release Ophthalmic Drugs Revenue and Market Share by Application (2021-2026)

2.4.5.3 Global Sustained Release Ophthalmic Drugs Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Sustained Release Ophthalmic Drugs Breakdown Data by Company

3.1.1 Global Sustained Release Ophthalmic Drugs Annual Sales by Company (2021-2026)

3.1.2 Global Sustained Release Ophthalmic Drugs Sales Market Share by Company (2021-2026)

3.2 Global Sustained Release Ophthalmic Drugs Annual Revenue by Company (2021-2026)

3.2.1 Global Sustained Release Ophthalmic Drugs Revenue by Company (2021-2026)

3.2.2 Global Sustained Release Ophthalmic Drugs Revenue Market Share by Company (2021-2026)

3.3 Global Sustained Release Ophthalmic Drugs Sale Price by Company

3.4 Key Manufacturers Sustained Release Ophthalmic Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Sustained Release Ophthalmic Drugs Product Location Distribution

3.4.2 Players Sustained Release Ophthalmic Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SUSTAINED RELEASE OPHTHALMIC DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Sustained Release Ophthalmic Drugs Market Size by Geographic Region (2021-2026)

4.1.1 Global Sustained Release Ophthalmic Drugs Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Sustained Release Ophthalmic Drugs Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Sustained Release Ophthalmic Drugs Market Size by Country/Region (2021-2026)

4.2.1 Global Sustained Release Ophthalmic Drugs Annual Sales by Country/Region (2021-2026)

4.2.2 Global Sustained Release Ophthalmic Drugs Annual Revenue by Country/Region (2021-2026)

4.3 Americas Sustained Release Ophthalmic Drugs Sales Growth

4.4 APAC Sustained Release Ophthalmic Drugs Sales Growth

4.5 Europe Sustained Release Ophthalmic Drugs Sales Growth

4.6 Middle East & Africa Sustained Release Ophthalmic Drugs Sales Growth

5 AMERICAS

5.1 Americas Sustained Release Ophthalmic Drugs Sales by Country

5.1.1 Americas Sustained Release Ophthalmic Drugs Sales by Country (2021-2026)

5.1.2 Americas Sustained Release Ophthalmic Drugs Revenue by Country (2021-2026)

5.2 Americas Sustained Release Ophthalmic Drugs Sales by Type (2021-2026)

5.3 Americas Sustained Release Ophthalmic Drugs Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Sustained Release Ophthalmic Drugs Sales by Region

- 6.1.1 APAC Sustained Release Ophthalmic Drugs Sales by Region (2021-2026)
- 6.1.2 APAC Sustained Release Ophthalmic Drugs Revenue by Region (2021-2026)
- 6.2 APAC Sustained Release Ophthalmic Drugs Sales by Type (2021-2026)
- 6.3 APAC Sustained Release Ophthalmic Drugs Sales by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Sustained Release Ophthalmic Drugs by Country
 - 7.1.1 Europe Sustained Release Ophthalmic Drugs Sales by Country (2021-2026)
 - 7.1.2 Europe Sustained Release Ophthalmic Drugs Revenue by Country (2021-2026)
- 7.2 Europe Sustained Release Ophthalmic Drugs Sales by Type (2021-2026)
- 7.3 Europe Sustained Release Ophthalmic Drugs Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Sustained Release Ophthalmic Drugs by Country
 - 8.1.1 Middle East & Africa Sustained Release Ophthalmic Drugs Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Sustained Release Ophthalmic Drugs Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Sustained Release Ophthalmic Drugs Sales by Type (2021-2026)
- 8.3 Middle East & Africa Sustained Release Ophthalmic Drugs Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Sustained Release Ophthalmic Drugs

10.3 Manufacturing Process Analysis of Sustained Release Ophthalmic Drugs

10.4 Industry Chain Structure of Sustained Release Ophthalmic Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Sustained Release Ophthalmic Drugs Distributors

11.3 Sustained Release Ophthalmic Drugs Customer

12 WORLD FORECAST REVIEW FOR SUSTAINED RELEASE OPHTHALMIC DRUGS BY GEOGRAPHIC REGION

12.1 Global Sustained Release Ophthalmic Drugs Market Size Forecast by Region

12.1.1 Global Sustained Release Ophthalmic Drugs Forecast by Region (2027-2032)

12.1.2 Global Sustained Release Ophthalmic Drugs Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Sustained Release Ophthalmic Drugs Forecast by Type (2027-2032)

12.7 Global Sustained Release Ophthalmic Drugs Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 EyePoint

13.1.1 EyePoint Company Information

13.1.2 EyePoint Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

13.1.3 EyePoint Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 EyePoint Main Business Overview

13.1.5 EyePoint Latest Developments

13.2 AbbVie

13.2.1 AbbVie Company Information

13.2.2 AbbVie Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

13.2.3 AbbVie Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 AbbVie Main Business Overview

13.2.5 AbbVie Latest Developments

13.3 Ocular Therapeutix

13.3.1 Ocular Therapeutix Company Information

13.3.2 Ocular Therapeutix Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

13.3.3 Ocular Therapeutix Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Ocular Therapeutix Main Business Overview

13.3.5 Ocular Therapeutix Latest Developments

13.4 Neurotech Pharmaceuticals

13.4.1 Neurotech Pharmaceuticals Company Information

13.4.2 Neurotech Pharmaceuticals Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

13.4.3 Neurotech Pharmaceuticals Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Neurotech Pharmaceuticals Main Business Overview

13.4.5 Neurotech Pharmaceuticals Latest Developments

13.5 Santen Pharmaceutical

13.5.1 Santen Pharmaceutical Company Information

13.5.2 Santen Pharmaceutical Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

13.5.3 Santen Pharmaceutical Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.5.4 Santen Pharmaceutical Main Business Overview
- 13.5.5 Santen Pharmaceutical Latest Developments
- 13.6 Clearside Biomedical
 - 13.6.1 Clearside Biomedical Company Information
 - 13.6.2 Clearside Biomedical Sustained Release Ophthalmic Drugs Product Portfolios and Specifications
 - 13.6.3 Clearside Biomedical Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Clearside Biomedical Main Business Overview
 - 13.6.5 Clearside Biomedical Latest Developments
- 13.7 PolyActiva
 - 13.7.1 PolyActiva Company Information
 - 13.7.2 PolyActiva Sustained Release Ophthalmic Drugs Product Portfolios and Specifications
 - 13.7.3 PolyActiva Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 PolyActiva Main Business Overview
 - 13.7.5 PolyActiva Latest Developments
- 13.8 Kodiak Sciences
 - 13.8.1 Kodiak Sciences Company Information
 - 13.8.2 Kodiak Sciences Sustained Release Ophthalmic Drugs Product Portfolios and Specifications
 - 13.8.3 Kodiak Sciences Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 Kodiak Sciences Main Business Overview
 - 13.8.5 Kodiak Sciences Latest Developments
- 13.9 Adverum
 - 13.9.1 Adverum Company Information
 - 13.9.2 Adverum Sustained Release Ophthalmic Drugs Product Portfolios and Specifications
 - 13.9.3 Adverum Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 Adverum Main Business Overview
 - 13.9.5 Adverum Latest Developments
- 13.10 Bausch + Lomb
 - 13.10.1 Bausch + Lomb Company Information
 - 13.10.2 Bausch + Lomb Sustained Release Ophthalmic Drugs Product Portfolios and Specifications
 - 13.10.3 Bausch + Lomb Sustained Release Ophthalmic Drugs Sales, Revenue, Price

and Gross Margin (2021-2026)

13.10.4 Bausch + Lomb Main Business Overview

13.10.5 Bausch + Lomb Latest Developments

13.11 Kanghong

13.11.1 Kanghong Company Information

13.11.2 Kanghong Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

13.11.3 Kanghong Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Kanghong Main Business Overview

13.11.5 Kanghong Latest Developments

13.12 Ocumension

13.12.1 Ocumension Company Information

13.12.2 Ocumension Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

13.12.3 Ocumension Sustained Release Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Ocumension Main Business Overview

13.12.5 Ocumension Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Sustained Release Ophthalmic Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Sustained Release Ophthalmic Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Implants

Table 4. Major Players of Punctal Plug

Table 5. Major Players of Liposome

Table 6. Major Players of In Situ Gel

Table 7. Global Sustained Release Ophthalmic Drugs Sales by Type (2021-2026) & (K Dose)

Table 8. Global Sustained Release Ophthalmic Drugs Sales Market Share by Type (2021-2026)

Table 9. Global Sustained Release Ophthalmic Drugs Revenue by Type (2021-2026) & (\$ million)

Table 10. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Type (2021-2026)

Table 11. Global Sustained Release Ophthalmic Drugs Sale Price by Type (2021-2026) & (US\$/Dose)

Table 12. Major Players of Diffusion Controlled Drug

Table 13. Major Players of Degradation Controlled Drug

Table 14. Major Players of Swelling Controlled Drug

Table 15. Major Players of Stimuli Responsive Drug

Table 16. Global Sustained Release Ophthalmic Drugs Sales by Release Mechanism (2021-2026) & (K Dose)

Table 17. Global Sustained Release Ophthalmic Drugs Sales Market Share by Release Mechanism (2021-2026)

Table 18. Global Sustained Release Ophthalmic Drugs Revenue by Release Mechanism (2021-2026) & (\$ million)

Table 19. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Release Mechanism (2021-2026)

Table 20. Global Sustained Release Ophthalmic Drugs Sale Price by Release Mechanism (2021-2026) & (US\$/Dose)

Table 21. Global Sustained Release Ophthalmic Drugs Sale by Application (2021-2026) & (K Dose)

Table 22. Global Sustained Release Ophthalmic Drugs Sale Market Share by

Application (2021-2026)

Table 23. Global Sustained Release Ophthalmic Drugs Revenue by Application (2021-2026) & (\$ million)

Table 24. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Application (2021-2026)

Table 25. Global Sustained Release Ophthalmic Drugs Sale Price by Application (2021-2026) & (US\$/Dose)

Table 26. Global Sustained Release Ophthalmic Drugs Sales by Company (2021-2026) & (K Dose)

Table 27. Global Sustained Release Ophthalmic Drugs Sales Market Share by Company (2021-2026)

Table 28. Global Sustained Release Ophthalmic Drugs Revenue by Company (2021-2026) & (\$ millions)

Table 29. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Company (2021-2026)

Table 30. Global Sustained Release Ophthalmic Drugs Sale Price by Company (2021-2026) & (US\$/Dose)

Table 31. Key Manufacturers Sustained Release Ophthalmic Drugs Producing Area Distribution and Sales Area

Table 32. Players Sustained Release Ophthalmic Drugs Products Offered

Table 33. Sustained Release Ophthalmic Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 34. New Products and Potential Entrants

Table 35. Market M&A Activity & Strategy

Table 36. Global Sustained Release Ophthalmic Drugs Sales by Geographic Region (2021-2026) & (K Dose)

Table 37. Global Sustained Release Ophthalmic Drugs Sales Market Share Geographic Region (2021-2026)

Table 38. Global Sustained Release Ophthalmic Drugs Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 39. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Geographic Region (2021-2026)

Table 40. Global Sustained Release Ophthalmic Drugs Sales by Country/Region (2021-2026) & (K Dose)

Table 41. Global Sustained Release Ophthalmic Drugs Sales Market Share by Country/Region (2021-2026)

Table 42. Global Sustained Release Ophthalmic Drugs Revenue by Country/Region (2021-2026) & (\$ millions)

Table 43. Global Sustained Release Ophthalmic Drugs Revenue Market Share by

Country/Region (2021-2026)

Table 44. Americas Sustained Release Ophthalmic Drugs Sales by Country (2021-2026) & (K Dose)

Table 45. Americas Sustained Release Ophthalmic Drugs Sales Market Share by Country (2021-2026)

Table 46. Americas Sustained Release Ophthalmic Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 47. Americas Sustained Release Ophthalmic Drugs Sales by Type (2021-2026) & (K Dose)

Table 48. Americas Sustained Release Ophthalmic Drugs Sales by Application (2021-2026) & (K Dose)

Table 49. APAC Sustained Release Ophthalmic Drugs Sales by Region (2021-2026) & (K Dose)

Table 50. APAC Sustained Release Ophthalmic Drugs Sales Market Share by Region (2021-2026)

Table 51. APAC Sustained Release Ophthalmic Drugs Revenue by Region (2021-2026) & (\$ millions)

Table 52. APAC Sustained Release Ophthalmic Drugs Sales by Type (2021-2026) & (K Dose)

Table 53. APAC Sustained Release Ophthalmic Drugs Sales by Application (2021-2026) & (K Dose)

Table 54. Europe Sustained Release Ophthalmic Drugs Sales by Country (2021-2026) & (K Dose)

Table 55. Europe Sustained Release Ophthalmic Drugs Revenue by Country (2021-2026) & (\$ millions)

Table 56. Europe Sustained Release Ophthalmic Drugs Sales by Type (2021-2026) & (K Dose)

Table 57. Europe Sustained Release Ophthalmic Drugs Sales by Application (2021-2026) & (K Dose)

Table 58. Middle East & Africa Sustained Release Ophthalmic Drugs Sales by Country (2021-2026) & (K Dose)

Table 59. Middle East & Africa Sustained Release Ophthalmic Drugs Revenue Market Share by Country (2021-2026)

Table 60. Middle East & Africa Sustained Release Ophthalmic Drugs Sales by Type (2021-2026) & (K Dose)

Table 61. Middle East & Africa Sustained Release Ophthalmic Drugs Sales by Application (2021-2026) & (K Dose)

Table 62. Key Market Drivers & Growth Opportunities of Sustained Release Ophthalmic Drugs

Table 63. Key Market Challenges & Risks of Sustained Release Ophthalmic Drugs

Table 64. Key Industry Trends of Sustained Release Ophthalmic Drugs

Table 65. Sustained Release Ophthalmic Drugs Raw Material

Table 66. Key Suppliers of Raw Materials

Table 67. Sustained Release Ophthalmic Drugs Distributors List

Table 68. Sustained Release Ophthalmic Drugs Customer List

Table 69. Global Sustained Release Ophthalmic Drugs Sales Forecast by Region
(2027-2032) & (K Dose)

Table 70. Global Sustained Release Ophthalmic Drugs Revenue Forecast by Region
(2027-2032) & (\$ millions)

Table 71. Americas Sustained Release Ophthalmic Drugs Sales Forecast by Country
(2027-2032) & (K Dose)

Table 72. Americas Sustained Release Ophthalmic Drugs Annual Revenue Forecast by
Country (2027-2032) & (\$ millions)

Table 73. APAC Sustained Release Ophthalmic Drugs Sales Forecast by Region
(2027-2032) & (K Dose)

Table 74. APAC Sustained Release Ophthalmic Drugs Annual Revenue Forecast by
Region (2027-2032) & (\$ millions)

Table 75. Europe Sustained Release Ophthalmic Drugs Sales Forecast by Country
(2027-2032) & (K Dose)

Table 76. Europe Sustained Release Ophthalmic Drugs Revenue Forecast by Country
(2027-2032) & (\$ millions)

Table 77. Middle East & Africa Sustained Release Ophthalmic Drugs Sales Forecast by
Country (2027-2032) & (K Dose)

Table 78. Middle East & Africa Sustained Release Ophthalmic Drugs Revenue Forecast
by Country (2027-2032) & (\$ millions)

Table 79. Global Sustained Release Ophthalmic Drugs Sales Forecast by Type
(2027-2032) & (K Dose)

Table 80. Global Sustained Release Ophthalmic Drugs Revenue Forecast by Type
(2027-2032) & (\$ millions)

Table 81. Global Sustained Release Ophthalmic Drugs Sales Forecast by Application
(2027-2032) & (K Dose)

Table 82. Global Sustained Release Ophthalmic Drugs Revenue Forecast by
Application (2027-2032) & (\$ millions)

Table 83. EyePoint Basic Information, Sustained Release Ophthalmic Drugs
Manufacturing Base, Sales Area and Its Competitors

Table 84. EyePoint Sustained Release Ophthalmic Drugs Product Portfolios and
Specifications

Table 85. EyePoint Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$

Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 86. EyePoint Main Business

Table 87. EyePoint Latest Developments

Table 88. AbbVie Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 89. AbbVie Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 90. AbbVie Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 91. AbbVie Main Business

Table 92. AbbVie Latest Developments

Table 93. Ocular Therapeutix Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 94. Ocular Therapeutix Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 95. Ocular Therapeutix Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 96. Ocular Therapeutix Main Business

Table 97. Ocular Therapeutix Latest Developments

Table 98. Neurotech Pharmaceuticals Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 99. Neurotech Pharmaceuticals Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 100. Neurotech Pharmaceuticals Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 101. Neurotech Pharmaceuticals Main Business

Table 102. Neurotech Pharmaceuticals Latest Developments

Table 103. Santen Pharmaceutical Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 104. Santen Pharmaceutical Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 105. Santen Pharmaceutical Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 106. Santen Pharmaceutical Main Business

Table 107. Santen Pharmaceutical Latest Developments

Table 108. Clearside Biomedical Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 109. Clearside Biomedical Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 110. Clearside Biomedical Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 111. Clearside Biomedical Main Business

Table 112. Clearside Biomedical Latest Developments

Table 113. PolyActiva Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 114. PolyActiva Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 115. PolyActiva Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 116. PolyActiva Main Business

Table 117. PolyActiva Latest Developments

Table 118. Kodiak Sciences Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 119. Kodiak Sciences Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 120. Kodiak Sciences Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 121. Kodiak Sciences Main Business

Table 122. Kodiak Sciences Latest Developments

Table 123. Adverum Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 124. Adverum Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 125. Adverum Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 126. Adverum Main Business

Table 127. Adverum Latest Developments

Table 128. Bausch + Lomb Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 129. Bausch + Lomb Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 130. Bausch + Lomb Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 131. Bausch + Lomb Main Business

Table 132. Bausch + Lomb Latest Developments

Table 133. Kanghong Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 134. Kanghong Sustained Release Ophthalmic Drugs Product Portfolios and

Specifications

Table 135. Kanghong Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 136. Kanghong Main Business

Table 137. Kanghong Latest Developments

Table 138. Ocumension Basic Information, Sustained Release Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors

Table 139. Ocumension Sustained Release Ophthalmic Drugs Product Portfolios and Specifications

Table 140. Ocumension Sustained Release Ophthalmic Drugs Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 141. Ocumension Main Business

Table 142. Ocumension Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Sustained Release Ophthalmic Drugs
- Figure 2. Sustained Release Ophthalmic Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Sustained Release Ophthalmic Drugs Sales Growth Rate 2021-2032 (K Dose)
- Figure 7. Global Sustained Release Ophthalmic Drugs Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Sustained Release Ophthalmic Drugs Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Sustained Release Ophthalmic Drugs Sales Market Share by Country/Region (2025)
- Figure 10. Sustained Release Ophthalmic Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Implants
- Figure 12. Product Picture of Punctal Plug
- Figure 13. Product Picture of Liposome
- Figure 14. Product Picture of In Situ Gel
- Figure 15. Global Sustained Release Ophthalmic Drugs Sales Market Share by Type in 2026
- Figure 16. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Type (2021-2026)
- Figure 17. Product Picture of Diffusion Controlled Drug
- Figure 18. Product Picture of Degradation Controlled Drug
- Figure 19. Product Picture of Swelling Controlled Drug
- Figure 20. Product Picture of Stimuli Responsive Drug
- Figure 21. Global Sustained Release Ophthalmic Drugs Sales Market Share by Release Mechanism in 2026
- Figure 22. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Release Mechanism (2021-2026)
- Figure 23. Sustained Release Ophthalmic Drugs Consumed in Cataract Therapy
- Figure 24. Global Sustained Release Ophthalmic Drugs Market: Cataract Therapy (2021-2026) & (K Dose)
- Figure 25. Sustained Release Ophthalmic Drugs Consumed in Glaucoma Therapy

Figure 26. Global Sustained Release Ophthalmic Drugs Market: Glaucoma Therapy (2021-2026) & (K Dose)

Figure 27. Sustained Release Ophthalmic Drugs Consumed in Dry Eye Disease Therapy

Figure 28. Global Sustained Release Ophthalmic Drugs Market: Dry Eye Disease Therapy (2021-2026) & (K Dose)

Figure 29. Sustained Release Ophthalmic Drugs Consumed in Others

Figure 30. Global Sustained Release Ophthalmic Drugs Market: Others (2021-2026) & (K Dose)

Figure 31. Global Sustained Release Ophthalmic Drugs Sale Market Share by Application (2025)

Figure 32. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Application in 2025

Figure 33. Sustained Release Ophthalmic Drugs Sales by Company in 2025 (K Dose)

Figure 34. Global Sustained Release Ophthalmic Drugs Sales Market Share by Company in 2025

Figure 35. Sustained Release Ophthalmic Drugs Revenue by Company in 2025 (\$ millions)

Figure 36. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Company in 2025

Figure 37. Global Sustained Release Ophthalmic Drugs Sales Market Share by Geographic Region (2021-2026)

Figure 38. Global Sustained Release Ophthalmic Drugs Revenue Market Share by Geographic Region in 2025

Figure 39. Americas Sustained Release Ophthalmic Drugs Sales 2021-2026 (K Dose)

Figure 40. Americas Sustained Release Ophthalmic Drugs Revenue 2021-2026 (\$ millions)

Figure 41. APAC Sustained Release Ophthalmic Drugs Sales 2021-2026 (K Dose)

Figure 42. APAC Sustained Release Ophthalmic Drugs Revenue 2021-2026 (\$ millions)

Figure 43. Europe Sustained Release Ophthalmic Drugs Sales 2021-2026 (K Dose)

Figure 44. Europe Sustained Release Ophthalmic Drugs Revenue 2021-2026 (\$ millions)

Figure 45. Middle East & Africa Sustained Release Ophthalmic Drugs Sales 2021-2026 (K Dose)

Figure 46. Middle East & Africa Sustained Release Ophthalmic Drugs Revenue 2021-2026 (\$ millions)

Figure 47. Americas Sustained Release Ophthalmic Drugs Sales Market Share by Country in 2025

Figure 48. Americas Sustained Release Ophthalmic Drugs Revenue Market Share by

Country (2021-2026)

Figure 49. Americas Sustained Release Ophthalmic Drugs Sales Market Share by Type (2021-2026)

Figure 50. Americas Sustained Release Ophthalmic Drugs Sales Market Share by Application (2021-2026)

Figure 51. United States Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 52. Canada Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 53. Mexico Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 54. Brazil Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 55. APAC Sustained Release Ophthalmic Drugs Sales Market Share by Region in 2025

Figure 56. APAC Sustained Release Ophthalmic Drugs Revenue Market Share by Region (2021-2026)

Figure 57. APAC Sustained Release Ophthalmic Drugs Sales Market Share by Type (2021-2026)

Figure 58. APAC Sustained Release Ophthalmic Drugs Sales Market Share by Application (2021-2026)

Figure 59. China Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 60. Japan Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 61. South Korea Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 62. Southeast Asia Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 63. India Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 64. Australia Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 65. China Taiwan Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 66. Europe Sustained Release Ophthalmic Drugs Sales Market Share by Country in 2025

Figure 67. Europe Sustained Release Ophthalmic Drugs Revenue Market Share by Country (2021-2026)

Figure 68. Europe Sustained Release Ophthalmic Drugs Sales Market Share by Type (2021-2026)

Figure 69. Europe Sustained Release Ophthalmic Drugs Sales Market Share by Application (2021-2026)

Figure 70. Germany Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 71. France Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 72. UK Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 73. Italy Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 74. Russia Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 75. Middle East & Africa Sustained Release Ophthalmic Drugs Sales Market Share by Country (2021-2026)

Figure 76. Middle East & Africa Sustained Release Ophthalmic Drugs Sales Market Share by Type (2021-2026)

Figure 77. Middle East & Africa Sustained Release Ophthalmic Drugs Sales Market Share by Application (2021-2026)

Figure 78. Egypt Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 79. South Africa Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 80. Israel Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 81. Turkey Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 82. GCC Countries Sustained Release Ophthalmic Drugs Revenue Growth 2021-2026 (\$ millions)

Figure 83. Manufacturing Cost Structure Analysis of Sustained Release Ophthalmic Drugs in 2026

Figure 84. Manufacturing Process Analysis of Sustained Release Ophthalmic Drugs

Figure 85. Industry Chain Structure of Sustained Release Ophthalmic Drugs

Figure 86. Channels of Distribution

Figure 87. Global Sustained Release Ophthalmic Drugs Sales Market Forecast by Region (2027-2032)

Figure 88. Global Sustained Release Ophthalmic Drugs Revenue Market Share Forecast by Region (2027-2032)

Figure 89. Global Sustained Release Ophthalmic Drugs Sales Market Share Forecast by Type (2027-2032)

Figure 90. Global Sustained Release Ophthalmic Drugs Revenue Market Share Forecast by Type (2027-2032)

Figure 91. Global Sustained Release Ophthalmic Drugs Sales Market Share Forecast by Application (2027-2032)

Figure 92. Global Sustained Release Ophthalmic Drugs Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Sustained Release Ophthalmic Drugs Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G29E525E04BDEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G29E525E04BDEN.html>